Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million in milestones.

The deal gives Eli Lilly and Co. (NYSE:LLY) oral SSTR4 agonist CNTX-0290, which Centrexion

Read the full 503 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE